These findings open new perspectives for BC management, since basal-like BC include most of triple negative BC, that do not express ER, PgR and HER2 being therefore the hardest to treat: in this scenario, hERG1 presence might be helpful for targeted therapies. This evidence concerns the gene KCNH2 and breast cancer.